Equities

Gilead Sciences Inc

0QYQ:LSE

Gilead Sciences Inc

  • Price (USD)67.20
  • Today's Change0.00 / 0.00%
  • Shares traded1.42k
  • 1 Year change-13.55%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 18:10 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Gilead Sciences Inc had relatively flat revenues (27.28bn to 27.12bn), though the company grew net income 23.34% from 4.59bn to 5.66bn.
Gross margin75.78%
Net profit margin1.66%
Operating margin5.75%
Return on assets0.77%
Return on equity2.51%
Return on investment0.96%
More ▼

Cash flow in USDView more

In 2023, Gilead Sciences Inc increased its cash reserves by 12.44%, or 673.00m. The company earned 8.01bn from its operations for a Cash Flow Margin of 29.53%. In addition the company used 2.27bn on investing activities and also paid 5.13bn in financing cash flows.
Cash flow per share2.55
Price/Cash flow per share26.35
Book value per share14.08
Tangible book value per share-11.40
More ▼

Balance sheet in USDView more

Gilead Sciences Inc has a Debt to Total Capital ratio of 59.07%, a lower figure than the previous year's 109.33%.
Current ratio1.08
Quick ratio0.9365
Total debt/total equity1.44
Total debt/total capital0.5907
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)3.91%
Div growth rate (5 year)5.64%
Payout ratio (TTM)792.77%
EPS growth(5 years)1.53
EPS (TTM) vs
TTM 1 year ago		-91.87
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.